488 related articles for article (PubMed ID: 29980618)
1. Revisiting IL-2: Biology and therapeutic prospects.
Abbas AK; Trotta E; R Simeonov D; Marson A; Bluestone JA
Sci Immunol; 2018 Jul; 3(25):. PubMed ID: 29980618
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
[TBL] [Abstract][Full Text] [Related]
4. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
5. Cytokines affecting CD4(+) T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4(+)CD25(+) Treg.
Plain KM; Verma ND; Tran GT; Nomura M; Boyd R; Robinson CM; Hodgkinson SJ; Hall BM
Transpl Immunol; 2013 Dec; 29(1-4):51-9. PubMed ID: 24139939
[TBL] [Abstract][Full Text] [Related]
6. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
7. IL-2 promotes the function of memory-like autoregulatory CD8+ T cells but suppresses their development via FoxP3+ Treg cells.
Shameli A; Yamanouchi J; Tsai S; Yang Y; Clemente-Casares X; Moore A; Serra P; Santamaria P
Eur J Immunol; 2013 Feb; 43(2):394-403. PubMed ID: 23180662
[TBL] [Abstract][Full Text] [Related]
8. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells.
Cheng G; Yu A; Malek TR
Immunol Rev; 2011 May; 241(1):63-76. PubMed ID: 21488890
[TBL] [Abstract][Full Text] [Related]
9. Application of IL-2 therapy to target T regulatory cell function.
Shevach EM
Trends Immunol; 2012 Dec; 33(12):626-32. PubMed ID: 22951308
[TBL] [Abstract][Full Text] [Related]
10. IL-2Rbeta links IL-2R signaling with Foxp3 expression.
Soper DM; Kasprowicz DJ; Ziegler SF
Eur J Immunol; 2007 Jul; 37(7):1817-26. PubMed ID: 17559173
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
12. In vivo maintenance of human regulatory T cells during CD25 blockade.
Huss DJ; Mehta DS; Sharma A; You X; Riester KA; Sheridan JP; Amaravadi LS; Elkins JS; Fontenot JD
J Immunol; 2015 Jan; 194(1):84-92. PubMed ID: 25416807
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.
Yu H; Paiva R; Flavell RA
Immunology; 2018 Feb; 153(2):161-170. PubMed ID: 29155454
[TBL] [Abstract][Full Text] [Related]
14. Deficient SOCS3 expression in CD4+CD25+FoxP3+ regulatory T cells and SOCS3-mediated suppression of Treg function.
Pillemer BB; Xu H; Oriss TB; Qi Z; Ray A
Eur J Immunol; 2007 Aug; 37(8):2082-9. PubMed ID: 17621372
[TBL] [Abstract][Full Text] [Related]
15. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
Brandenburg S; Takahashi T; de la Rosa M; Janke M; Karsten G; Muzzulini T; Orinska Z; Bulfone-Paus S; Scheffold A
Eur J Immunol; 2008 Jun; 38(6):1643-53. PubMed ID: 18493984
[TBL] [Abstract][Full Text] [Related]
16. Induction of antigen specific CD4(+)CD25(+)Foxp3(+)T regulatory cells from naïve natural thymic derived T regulatory cells.
Hall BM; Tran GT; Robinson CM; Hodgkinson SJ
Int Immunopharmacol; 2015 Oct; 28(2):875-86. PubMed ID: 25882104
[TBL] [Abstract][Full Text] [Related]
17. IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA; Buckner JH; Greenbaum CJ
Clin Immunol; 2013 Dec; 149(3):324-31. PubMed ID: 23499139
[TBL] [Abstract][Full Text] [Related]
18. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI
Int J Hematol; 2018 Feb; 107(2):130-137. PubMed ID: 29234980
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis.
Murawski MR; Litherland SA; Clare-Salzler MJ; Davoodi-Semiromi A
Ann N Y Acad Sci; 2006 Oct; 1079():198-204. PubMed ID: 17130555
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2: Biology, Design and Application.
Arenas-Ramirez N; Woytschak J; Boyman O
Trends Immunol; 2015 Dec; 36(12):763-777. PubMed ID: 26572555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
